H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations

Phase 1

Completed

Conditions: Bioequivalence Study in Healthy Subjects

Interventions: Drug: 0.5 mg Flupentixol film-coated tablet (test treatment)
Drug: 1 mg Flupentixol film-coated tablet (test treatment)
Drug: 5 mg Flupentixol film-coated tablet (test treatment)
Drug: 0.5 mg Flupentixol coated tablet (reference treatment)
Drug: 5 mg Flupentixol coated tablet (reference treatment)
Drug: 1 mg Flupentixol coated tablet (reference treatment)

First Posted Date: 2016-01-21

Last Posted Date: 2016-07-26

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 84

Registration Number: NCT02660840

Locations: 🇷🇺
RU801, Moscow, Russian Federation

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: 0.2 mg Lu AE04621
Drug: 1.0 mg Lu AE04621
Drug: 0.04 mg Lu AE04621
Drug: 0.6 mg Lu AE04621
Drug: 1.2 mg Lu AE04621
Drug: 0.8 mg Lu AE04621
Drug: 0.4 mg Lu AE04621
Drug: 0.08 mg Lu AE04621

First Posted Date: 2016-01-07

Last Posted Date: 2021-02-24

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 15

Registration Number: NCT02649608

Locations: 🇺🇸
US1251, Hallandale Beach, Florida, United States
🇺🇸
US1126, Orlando, Florida, United States
🇺🇸
US1352, Chicago, Illinois, United States

and more 1 locations

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Phase 4

Completed

Conditions: Symptomatic Neurogenic Orthostatic Hypotension

Interventions: Drug: Droxidopa capsules
Drug: Placebo capsules

First Posted Date: 2015-10-26

Last Posted Date: 2023-08-23

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 453

Registration Number: NCT02586623

Locations: 🇺🇸
Sutter East Bay Medical Foundation, Berkeley, California, United States
🇺🇸
New Life Medical Research Center, Miami Lakes, Florida, United States
🇺🇸
Nothern Michigan Neurology, Traverse City, Michigan, United States

and more 164 locations

Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

Phase 4

Completed

Conditions: Alzheimer Dementia (AD)

Interventions: Drug: Memantine (twice daily)
Drug: Memantine (once daily)

First Posted Date: 2015-09-18

Last Posted Date: 2019-03-14

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 62

Registration Number: NCT02553928

Locations: 🇨🇳
CN001, Beijing, China
🇨🇳
CN006, Fujian, China
🇨🇳
CN003, Zhejiang, China

and more 3 locations

Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: ldalopirdine 120 mg
Drug: Idalopirdine 360 mg
Drug: Moxifloxacin 400 mg

First Posted Date: 2015-05-06

Last Posted Date: 2015-09-22

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 76

Registration Number: NCT02436486

Locations: 🇫🇷
FR801, Rennes, France

Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [ethyl-1-14C]-idalopirdine
Drug: [benzyl-7-14C]-idalopirdine

First Posted Date: 2015-04-14

Last Posted Date: 2015-07-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 6

Registration Number: NCT02415907

Locations: 🇬🇧
GB802, Leeds, United Kingdom

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Phase 3

Completed

Conditions: Major Depression Disorder

Interventions: Drug: Adjunct brexpiprazole
Drug: ADT

First Posted Date: 2015-03-27

Last Posted Date: 2017-08-10

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 132

Registration Number: NCT02400346

Locations: 🇫🇮
FI003, Oulu, Finland
🇩🇪
DE001, Schwerin, Germany
🇩🇪
DE008, Berlin, Germany

and more 31 locations

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Phase 1

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: Lu AF20513, medium dose
Drug: Lu AF20513, low dose
Drug: Lu AF20513, high dose
Drug: Lu AF20513, double high dose

First Posted Date: 2015-03-13

Last Posted Date: 2019-11-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 50

Registration Number: NCT02388152

Locations: 🇸🇪
SE001, Stockholm, Sweden
🇫🇮
FI001, Turku, Finland
🇦🇹
AT001, Wien, Austria

and more 2 locations

Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Vortioxetine 20 mg multiple dose
Drug: Vortioxetine 10 mg single dose
Drug: Vortioxetine 10 mg multiple dose
Drug: Vortioxetine 20 mg single dose

First Posted Date: 2015-03-12

Last Posted Date: 2015-05-19

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 64

Registration Number: NCT02386488

Locations: 🇨🇳
CB801, Chengdu, China

Bioequivalence Study of Idalopirdine Tablets 60 mg

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Idalopirdine 60 mg formulation B (reference)
Drug: Idalopirdine 60 mg formulation A (test)

First Posted Date: 2015-02-26

Last Posted Date: 2015-05-07

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 30

Registration Number: NCT02371707

Locations: 🇬🇧
Covance, Leeds, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy